Dermatologic Adverse Events in EGFR-TKIs: A Real-World Analysis

This study analyzed the FDA Adverse Events Reporting System (FAERS) to identify dermatologic adverse events (DAEs) associated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) used in treating non-small cell lung cancer (NSCLC) that are not listed on drug labels. The analysis covered data from 2003 to 2023 for five EGFR-TKIs: osimertinib, afatinib, erlotinib, gefitinib, and mobocertinib. Out of 67,480 adverse events reported, 30.3% (20,426) were DAEs. The study identified previously unlisted DAEs, including skin issues (such as skin fissures and eczema), nail problems (like onychalgia), and hair disorders (including abnormal hair growth). These findings provide valuable insights for clinicians to better inform patients about potential side effects, enhancing patient understanding and management of expectations during treatment.